Related Experiment Video
Updated: Jan 17, 2026
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
Investigating the Role of sHLA-G in Immunopathogenesis and Predicting Gastroesophageal Reflux Disease
Wafaa Hazim Salih1, Huda Saleem Hantoosh Hameed Al-Khalidy2, Batool Mutar Mahdi3
1Department of Microbiology, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
Background:
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disease in which the patients may be asymptomatic or complain of heartburn and regurgitation or pulmonary symptoms. Aim of the study: Examine the serum level of soluble HLA-G (sHLA-G) in patients with GERD, which can be used as a biomarker for early detection of GERD.
Methods:
The study was a case-control prospective study that enrolled 40 patients who consulted the Gastroenterology Unit-Al-Kindy Teaching Hospital and were diagnosed with GERD by their physician. They were compared with 40 control healthy individuals from January 2023 to May 2024. Serum samples were used for quantitative assessment of sHLA-G using a sandwich enzyme-linked immunosorbent assay.
Results:
A higher proportion of females were observed in the GERD group compared with the control group (72.5% vs. 42.6%). This difference was statistically significant (P=0.006). A statistically non-significant difference was observed in sHLA-G levels between patients with GERD and healthy controls (P=0.158). The median sHLA-G level was non-significantly higher in patients with GERD (0.529 ng/mL) compared with the controls (0.523 ng/mL).
Conclusion:
The present study provides early evidence for an association between elevated sHLA-G levels and GERD with limited diagnostic value. It revealed a significant negative correlation between sHLA-G levels and sex. Further studies are needed to elucidate the mechanisms underlying this relationship and explore the potential of sHLA-G as a diagnostic or therapeutic target for GERD.
Related Concept Videos
01:29Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...